中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
—— | (-)-(1S)-(2,2,3-trimethylcyclopent-3-en-1-yl)acetic acid | 1727-66-8 | C10H16O2 | 168.236 |
(S)-2,2,3-三甲基环戊-3-烯-1-乙醛 | (S)-campholenic aldehyde | 23727-15-3 | C10H16O | 152.236 |
(+)-α-蒎烯 | (+)-α-pinene | 7785-70-8 | C10H16 | 136.237 |
(-)-α-蒎烯 | (-)-α-pinene | 7785-26-4 | C10H16 | 136.237 |
Inhibiting tyrosyl-DNA phosphodiesterase 1 (TDP1) is a promising strategy for increasing the effectiveness of existing antitumor therapy since it can remove the DNA lesions caused by anticancer drugs, which form covalent complexes with topoisomerase 1 (TOP1). Here, new adamantane–monoterpene conjugates with a 1,2,4-triazole or 1,3,4-thiadiazole linker core were synthesized, where (+)-and (−)-campholenic and (+)-camphor derivatives were used as monoterpene fragments. The campholenic derivatives 14a–14b and 15a–b showed activity against TDP1 at a low micromolar range with IC50 ~5–6 μM, whereas camphor-containing compounds 16 and 17 were ineffective. Surprisingly, all the compounds synthesized demonstrated a clear synergy with topotecan, a TOP1 poison, regardless of their ability to inhibit TDP1. These findings imply that different pathways of enhancing topotecan toxicity other than the inhibition of TDP1 can be realized.